Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Reprogramming of human pancreatic organoid cells into insulin-producing β-like cells by small molecules and in vitro transcribed modified mRNA encoding neurogenin 3 transcription factor

T. Koblas, I. Leontovyc, S. Loukotová, F. Saudek

. 2019 ; 65 (3) : 109-123.

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20005455

Reprogramming of non-endocrine pancreatic cells into insulin-producing cells represents a promising therapeutic approach for the restoration of endogenous insulin production in diabetic patients. In this paper, we report that human organoid cells derived from the pancreatic tissue can be reprogrammed into the insulin-producing cells (IPCs) by the combination of in vitro transcribed modified mRNA encoding transcription factor neurogenin 3 and small molecules modulating the epigenetic state and signalling pathways. Upon the reprogramming, IPCs formed 4.6 ± 1.2 % of the total cells and expressed typical markers (insulin, glucokinase, ABCC8, KCNJ11, SLC2A2, SLC30A8) and transcription factors (PDX1, NEUROD1, MAFA, NKX2.2, NKX6.1, PAX4, PAX6) needed for the proper function of pancreatic β-cells. Additionally, we have revealed a positive effect of ALK5 inhibitor RepSox on the overall reprogramming efficiency. However, the reprogrammed IPCs possessed only a partial insulin-secretory capacity, as they were not able to respond to the changes in the extracellular glucose concentration by increasing insulin secretion. Based on the achieved results we conclude that due to the incomplete reprogramming, the IPCs have immature character and only partial properties of native human β-cells.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20005455
003      
CZ-PrNML
005      
20200608143400.0
007      
ta
008      
200511s2019 xr d f 000 0|eng||
009      
AR
024    __
$a 10.14712/fb2019065030109 $2 doi
035    __
$a (PubMed)31638558
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Koblas, Tomáš $7 xx0070806 $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Reprogramming of human pancreatic organoid cells into insulin-producing β-like cells by small molecules and in vitro transcribed modified mRNA encoding neurogenin 3 transcription factor / $c T. Koblas, I. Leontovyc, S. Loukotová, F. Saudek
504    __
$a Literatura
520    9_
$a Reprogramming of non-endocrine pancreatic cells into insulin-producing cells represents a promising therapeutic approach for the restoration of endogenous insulin production in diabetic patients. In this paper, we report that human organoid cells derived from the pancreatic tissue can be reprogrammed into the insulin-producing cells (IPCs) by the combination of in vitro transcribed modified mRNA encoding transcription factor neurogenin 3 and small molecules modulating the epigenetic state and signalling pathways. Upon the reprogramming, IPCs formed 4.6 ± 1.2 % of the total cells and expressed typical markers (insulin, glucokinase, ABCC8, KCNJ11, SLC2A2, SLC30A8) and transcription factors (PDX1, NEUROD1, MAFA, NKX2.2, NKX6.1, PAX4, PAX6) needed for the proper function of pancreatic β-cells. Additionally, we have revealed a positive effect of ALK5 inhibitor RepSox on the overall reprogramming efficiency. However, the reprogrammed IPCs possessed only a partial insulin-secretory capacity, as they were not able to respond to the changes in the extracellular glucose concentration by increasing insulin secretion. Based on the achieved results we conclude that due to the incomplete reprogramming, the IPCs have immature character and only partial properties of native human β-cells.
650    _2
$a antigen AC133 $x metabolismus $7 D000071916
650    _2
$a dospělí $7 D000328
650    _2
$a transkripční faktory bHLH $x genetika $x metabolismus $7 D051792
650    _2
$a proliferace buněk $7 D049109
650    _2
$a přeprogramování buněk $x účinky léků $x genetika $7 D065150
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a inzulin $x biosyntéza $7 D007328
650    _2
$a beta-buňky $x cytologie $x účinky léků $7 D050417
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a proteiny nervové tkáně $x genetika $x metabolismus $7 D009419
650    _2
$a organoidy $x cytologie $7 D009940
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a knihovny malých molekul $x farmakologie $7 D054852
650    _2
$a genetická transkripce $x účinky léků $7 D014158
655    _2
$a časopisecké články $7 D016428
700    1_
$a Leontovyč, Ivan. $7 xx0239101 $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Loukotová, Šárka. $7 xx0248561 $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Saudek, František, $d 1955- $7 nlk20000083698 $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 65, č. 3 (2019), s. 109-123
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31638558 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5896/fb2019a0011.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200602164450 $b ABA008
999    __
$a ok $b bmc $g 1532564 $s 1095510
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 65 $c 3 $d 109-123 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
LZP    __
$b NLK118 $a Pubmed-20200511

Find record

Citation metrics

Logged in users only

Archiving options